KEYMED BIOSCIENCES INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.45 HKD | -2.07% |
|
-10.03% | -27.80% |
| 01:38pm | Keymed's Anti-Rhinosinusitis Drug Set For Priority Review in China | MT |
| Apr. 30 | Keymed Biosciences' Allergy Treatment NDA Accepted by NMPA | MT |
| Sales 2024 * | 109M 15.05M 117M | Sales 2025 * | 569M 78.58M 614M | Capitalization | 9.09B 1.26B 9.81B |
|---|---|---|---|---|---|
| Net income 2024 * | -830M -115M -895M | Net income 2025 * | -754M -104M -813M | EV / Sales 2024 * | 73.1 x |
| Net cash position 2024 * | 1.13B 157M 1.22B | Net cash position 2025 * | 1.58B 219M 1.71B | EV / Sales 2025 * | 13.2 x |
| P/E ratio 2024 * |
-11.2
x | P/E ratio 2025 * |
-12.4
x | Employees | 912 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61.99% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -2.07% | ||
| 1 week | -10.03% | ||
| Current month | +4.42% | ||
| 1 month | +21.61% | ||
| 3 months | +6.62% | ||
| 6 months | -31.89% | ||
| Current year | -27.80% |
1 week
35.30
39.90
1 month
32.1542.30
Current year
26.6049.20
1 year
26.6064.80
3 years
16.9082.85
5 years
16.9082.85
10 years
16.9082.85
| Managers | Title | Age | Since |
|---|---|---|---|
Bo Chen
CEO | Chief Executive Officer | 50 | 18-04-22 |
Yanrong Zhang
DFI | Director of Finance/CFO | 36 | 20-08-31 |
Joy Yan
CTO | Chief Tech/Sci/R&D Officer | 44 | 21-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cheuk Kin Law
BRD | Director/Board Member | 61 | 21-06-30 |
Yang Ke
BRD | Director/Board Member | 68 | 21-04-02 |
Bo Chen
CEO | Chief Executive Officer | 50 | 18-04-22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.54% | 4 M€ | -27.92% | ||
| 0.02% | 4 M€ | -4.41% | - | |
| 0.02% | 112 M€ | +4.73% | - | |
| 0.01% | 45 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-23 | 35.45 | -2.07% | 788 500 |
| 24-05-22 | 36.2 | +0.14% | 571,989 |
| 24-05-21 | 36.15 | -5.74% | 758,000 |
| 24-05-20 | 38.35 | +1.86% | 1,171,000 |
| 24-05-17 | 37.65 | -1.05% | 837,500 |
Delayed Quote Hong Kong S.E., May 23, 2024 at 04:08 am EDT
More quotes
Keymed Biosciences Inc is a China-based biotechnology company. The Company focuses on the independent discovery and development of innovative biological therapies that address underserved medical needs in the autoimmune and oncology therapeutic areas. The Company has mastered in-house drug discovery and development technologies, including an innovative antibody discovery platform and a proprietary novel T cell engager (nTCE) bispecific antibody platform. The Company has also established a fully integrated platform covering the key functions of biopharmaceutical development. The Company's main products include CM310, CM326 and CMG901.
Calendar
2024-08-26
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
32.88
CNY
Average target price
53.55
CNY
Spread / Average Target
+62.87%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -27.80% | 1.28B | |
| +10.60% | 115B | |
| +12.13% | 106B | |
| -4.39% | 24.69B | |
| -2.33% | 21.97B | |
| -6.03% | 19.27B | |
| -13.01% | 17.56B | |
| -40.50% | 17.32B | |
| +6.60% | 14.03B | |
| +30.97% | 12.13B |
- Stock Market
- Equities
- 2162 Stock
